How does a physician practice actually get acquired?
Through a management services organization, because in most states an investor cannot own the medical practice itself. The clinical entity stays under physician ownership and contracts with a separately owned services company for administration, real estate, staffing, billing and technology. The economics move through that contract.
Everything that makes this structure work and everything that puts it at risk sit in the same place: the management services agreement, and the arrangements that keep the clinical entity aligned with the services company over time. Those arrangements are what regulators have begun looking at.
The structure is not a technicality to be handled at signing. It determines who can sign what, what happens if a physician owner leaves, how transferable the arrangement is to a subsequent buyer, and what a lender can actually take security over. A practice that has never been through the exercise usually finds that its existing documents do not survive contact with an institutional acquirer.
The right time to fix it is before a process, not during one. Restructuring a clinical entity and a services company under time pressure, while a buyer watches, is the most reliable way we know to lose both time and price in this sector.
What has changed in the regulatory posture?
States have started legislating specifically about the structure rather than about ownership in general, and the drafting is getting more precise. Regulatory scrutiny of sponsor-backed management services arrangements intensified through the first half of 2026, with a wave of state-level bills addressing both transaction review and the arrangements themselves (Bass Berry and Sims, Healthcare Trends and Transactions, Q1 and Q2 2026).
One bill shows how specific this has become. Rhode Island Senate Bill 2459 would codify the state's corporate practice of medicine prohibition and regulate contracts between physician practices and management services organizations, including by banning stock transfer restriction agreements and prohibiting shareholders, directors and officers of a physician practice from serving in the same capacity at the services organization (same source). Those two provisions are precisely the mechanisms that hold the conventional structure together.
The point is not to predict which bills pass. It is that structural risk in this sector is now jurisdiction-specific and moving, so a multi-state platform carries a different risk profile from a single-state practice, and a buyer will price the difference. A seller who can produce a clean, state-by-state analysis of its own arrangements is answering a question the buyer was going to ask anyway.
There is a second consequence that owners under-anticipate. Regulatory attention lengthens processes. Diligence is already running one to three months longer where timelines have extended (SRS Acquiom and Mergermarket, published 23 February 2026), and a structure that needs a legal opinion in four states is not the transaction that closes fastest.
“In this sector we spend more time on the services agreement than on the multiple, and owners find that strange for about a week. Then the first buyer asks what happens to the arrangement if two of the four physician owners retire, and the conversation changes. That answer is worth more than a turn, and it is written down long before anybody talks about price.”
What actually drives value in a practice?
Payer mix and provider dependence, in that order, and both of them outrank specialty. A practice with a favourable and diversified payer mix and clinical capacity that does not depend on two people will clear above a higher-revenue practice that fails either test, in the same specialty and the same year.
Provider dependence is the key-man discount of this sector and it is measured, not asserted. A buyer will look at revenue per provider, the share of collections attributable to the top two clinicians, referral concentration, employment agreement terms and non-competition provisions, and the age profile of the clinical group. Where the answers cluster, the buyer either structures around it through earnouts and retention or discounts for it.
Payer mix drives the durability of the cash flow rather than its size. Reimbursement rates, the government share, contract renewal dates and any concentration in a single plan all move the underwriting, and they move it in ways that are outside the seller's control. A practice cannot fix its payer mix in the ninety days before a process; it can document it accurately, which is the difference between a discount and a re-trade.
On multiples, we would rather be useful than precise. Specialty-level multiple tables circulate widely in this sector and almost all of them aggregate disclosed transactions, which skew heavily toward larger deals and therefore overstate what a smaller practice will see. One dashboard puts the median across disclosed healthcare transactions at 12.7x enterprise value to EBITDA in Q1 2026, down from 13.0x a year earlier and 14.9x in Q1 2024 (FOCUS Investment Banking, healthcare multiples dashboard). Read that as a direction of travel for large disclosed deals, not as a quote for a practice with a million dollars of adjusted earnings.
| Area | What is measured | Effect on the transaction |
|---|---|---|
| Provider dependence | Revenue per provider, share of collections from the top two clinicians, referral concentration, employment and non-competition terms, age profile of the clinical group | Where dependence is concentrated, the buyer structures around it with retention and contingent consideration or discounts for it outright |
| Payer mix | Rate schedules, government share, contract renewal dates, concentration in any single plan | Determines the durability of cash flow; cannot be fixed before a process, only documented accurately |
| Structure | The management services agreement, the arrangements aligning the clinical entity, and their treatment in every state of operation | Governs transferability, security for lenders and, increasingly, regulatory exposure; multi-state platforms carry different risk from single-state practices |
| Scale and role | Whether the business is a platform or an add-on to an existing one | Across the middle market generally, platforms transacted at 7.6x against 6.5x for add-ons, the widest spread in that series |
Is capital still available for this sector?
Yes, and unusually so. Healthcare took a record 12.4% of institutional loan issuance in 2026, the largest share for any sector since 2015 (Sikich, Q2 2026 Credit Market Update, 13 July 2026, on PitchBook LCD data). At a moment when lenders were retreating from software and the overall sponsored issuance market fell 33%, healthcare gained share.
The equity side is consistent with that. Health and life sciences accounted for eighteen Americas listings in the first half of 2026, or 21% of the count, second only to energy (EY Global IPO Trends Q2 2026, published 7 July 2026). Sponsor activity in primary care, radiology, dental laboratories and adjacent services has continued through 2026 across multiple named platforms.
So the buyer set is intact, which is the first thing an owner wants to know. What has changed is the composition of it. This is a market where the largest platforms have done many transactions and the first-time acquirer is rare, which affects negotiating dynamics: a seller is usually negotiating against a counterparty that has executed this structure repeatedly and has standard positions on every document.
The corollary is that preparation matters more here than in a sector where buyers are learning as they go. An experienced acquirer moves fast on a well-prepared practice and moves the price on a poorly prepared one, because it knows exactly which findings justify a re-trade.
Why is the same sector leading restructuring?
Because the consolidation that made it attractive to lenders also made it leveraged, and the sector's revenue is exposed to reimbursement and labour cost in ways that leverage does not tolerate well. Healthcare providers and services accounted for 22% of out-of-court liability management exercises over the twelve months to 30 June 2026, more than double the next sector at 13%, and up from an equivalent share of 14% only a month earlier (PitchBook LCD, 10 July 2026).
That is not a reason to avoid the sector, and it is not evidence that every healthcare business is stressed. It is a reason to expect a lender to underwrite yours against a set of comparable situations it has already seen this year, and to ask sharper questions about payer concentration, labour cost trajectory and covenant headroom than it would in a sector without that record.
The sub-sector detail is where the useful information sits. Consensual, first-time restructurings in one healthcare sub-sector cleared at 70% to 90% first-lien recoveries in the second quarter of 2026, with first-lien debt reduced by 45% to 65% (Octus, Q2 2026, from lender filings), against an average of roughly 50 cents on the dollar across private credit restructurings generally (Octus, 11 May 2026, on a Q4 2025 reporting population). Which category a business falls into is determined by whether the problem is being addressed for the first time and whether there is a single lender group.
For a seller the practical read is straightforward. In a sector where lenders have recent, specific experience of things going wrong, the businesses that transact well are the ones that can demonstrate why they are not that case, in documents, before being asked.
As of August 2026
Sources: Bass Berry and Sims, Healthcare Trends and Transactions, Q1 and Q2 2026, for intensifying state-level scrutiny of sponsor-backed management services arrangements and for the provisions of Rhode Island Senate Bill 2459 codifying the corporate practice of medicine prohibition, banning stock transfer restriction agreements and prohibiting shareholders, directors and officers of a physician practice from serving in the same capacity at a management services organization; Sikich, Q2 2026 Credit Market Update, 13 July 2026, on PitchBook LCD data, for healthcare taking a record 12.4% of institutional loan issuance, the largest sector share since 2015, and for sponsored loan issuance falling 33%; PitchBook LCD, 10 July 2026, for healthcare providers and services accounting for 22% of liability management exercises over the twelve months to 30 June 2026 against 13% for the next sector, and for the equivalent healthcare share standing at 14% a month earlier; Octus, Q2 2026, from lender filings, for consensual first-time restructurings in one healthcare sub-sector clearing at 70% to 90% first-lien recoveries with first-lien debt reduced 45% to 65%, and Octus, 11 May 2026, on a Q4 2025 reporting population, for average private credit restructuring recoveries of roughly 50 cents on the dollar; EY Global IPO Trends Q2 2026, published 7 July 2026, for eighteen Americas health and life sciences listings in the first half of 2026 at 21% of the count; SRS Acquiom and Mergermarket, published 23 February 2026, for diligence timelines extending by one to three months where they have extended at all; FOCUS Investment Banking, healthcare multiples dashboard, for a median of 12.7x enterprise value to EBITDA across disclosed healthcare transactions in Q1 2026 against 13.0x a year earlier and 14.9x in Q1 2024, quoted here with the explicit caveat that disclosed-transaction medians skew toward larger deals; Mercer Capital, Middle Market Transaction Update Summer 2026, published July 2026 on GF Data figures as of Q1 2026, for platforms at 7.6x against add-ons at 6.5x across the middle market generally. Recovery evidence in this sector is genuinely contested between publishers measuring different populations, and both readings are presented rather than averaged. Companion articles on this site cover why healthcare services leads out-of-court restructuring, customer concentration, and what a quality of earnings report costs.